Two recent studies presented at the annual meeting of the European Association of Neurosurgical Societies (EANS) reinforced the benefits of using CyberKnife® radiosurgery to treat various neurological diseases.
Dr. Alfredo Conti, a neurosurgeon, led the first study. Dr. Conti used CyberKnife to treat perioptic meningiomas, a type of benign brain tumor that arises from the membranes surrounding the spinal cord and brain. The study results revealed that stereotactic radiosurgery using the CyberKnife system both maintained tumor control and preserved vision within 64 patients treated in 2-5 fractions from July 2007 to May 2010.
A second study, led by Prof. Pantaleo Romanelli, evaluated the clinical benefits of the CyberKnife system as a treatment for patients with trigeminal neuralgia (TN). Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which is responsible for transmitting sensations from the face to the brain. The study analyzed the treatment of 103 patients and showed that after 6 months over 90 percent of patients showed significant improvements in their symptoms. Results also showed that 24 patients, who had previously relapsed within two years from their first treatment, were successfully retreated using the CyberKnife system.
To learn more about these studies, click here.
If you are interested in learning more about CyberKnife and would like to read additional research and clinical trial information about treatment with CyberKnife, click here.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.